Last updated: September 26, 2026
PYLERA is a mature prescription therapy for Helicobacter pylori eradication containing bismuth subcitrate potassium, metronidazole, and tetracycline hydrochloride. Its commercial value is driven by continued demand for H. pylori treatment, physician preference for bismuth-based regimens, and resistance to clarithromycin and metronidazole. Its market position is constrained by low-cost component substitution, competing fixed-dose products such as Talicia, guideline-driven treatment changes, and limited disclosure of product-level sales.
AbbVie owns the commercial rights through its Allergan portfolio, but does not separately report PYLERA revenue. The product is therefore best analyzed as a mature, niche gastrointestinal franchise rather than a separately valued growth asset.
What is PYLERA and how is it used?
PYLERA is a fixed-dose combination capsule used with omeprazole for the eradication of H. pylori infection in adults. The standard regimen is three capsules four times daily for 10 days, combined with omeprazole twice daily.[1]
| Attribute |
PYLERA |
| Active ingredients |
Bismuth subcitrate potassium, metronidazole, tetracycline hydrochloride |
| Strength per capsule |
140 mg, 125 mg, and 125 mg, respectively |
| Dosage form |
Hard gelatin capsule |
| Approved use |
Eradication of H. pylori infection |
| FDA approval |
2006 |
| Standard duration |
10 days |
| Co-administered drug |
Omeprazole |
| Current owner |
AbbVie, through Allergan-related assets |
| Therapeutic market |
Gastroenterology, infectious disease |
| Primary competitive alternatives |
Generic bismuth quadruple therapy, Talicia, clarithromycin-based regimens where appropriate |
PYLERA packages three established generic molecules into one product. Its commercial proposition is convenience, standardized dosing, and a fixed bismuth-based regimen rather than molecular novelty.
When did PYLERA receive FDA approval and lose exclusivity?
The FDA approved PYLERA in 2006. Its original regulatory and patent exclusivity period has expired, placing the product in the mature-brand phase of its lifecycle.[1,2]
The product’s commercial protection has historically depended on patents covering the combination and its use, rather than on exclusivity for the individual active ingredients. Bismuth salts, metronidazole, tetracycline, and omeprazole are all long-established compounds with broad generic availability.
PYLERA exclusivity timeline
| Period |
Event |
Commercial impact |
| 2006 |
FDA approval of PYLERA |
Initial branded-market entry |
| 2006-2010s |
Branded promotion and patent protection |
Premium pricing relative to separate generic components |
| 2010s |
Ownership passed through specialty pharmaceutical transactions |
Commercial continuity under successive owners |
| 2020 |
AbbVie completed acquisition of Allergan |
PYLERA entered AbbVie’s gastrointestinal portfolio |
| Current period |
Mature product with no meaningful new-chemical-entity exclusivity |
Price, distribution, and physician familiarity are more important than regulatory exclusivity |
A precise current patent position should be determined from the FDA Orange Book and the U.S. Patent and Trademark Office records for the relevant NDA and patent family. The product does not have the profile of a medicine protected by an active composition-of-matter patent on a novel active ingredient.
What patents protect PYLERA?
PYLERA’s historic patent estate has centered on the fixed-dose combination, formulation, and treatment of H. pylori, not on the underlying active ingredients.
The relevant intellectual-property categories are:
- Combination-composition patents covering bismuth, metronidazole, and tetracycline in a single dosage form.
- Formulation patents covering capsule construction, ingredient ratios, or release characteristics.
- Method-of-use patents covering administration of the combination for H. pylori eradication.
- Regulatory exclusivity associated with the original NDA.
The economic value of these rights declines sharply after expiration because manufacturers can market the same active ingredients separately and may seek approval for a therapeutically equivalent fixed-dose product.
How strong is the PYLERA patent estate?
The estate is commercially moderate to weak for long-term protection.
Its strengths are:
- A recognized branded product with established clinical use.
- Potential formulation and combination claims that may create technical barriers for an exact fixed-dose copy.
- A large installed base of physicians familiar with bismuth-based eradication therapy.
Its weaknesses are:
- The active ingredients are old and widely available.
- The clinical regimen can be replicated using separate generic products.
- The product has no new chemical entity protection.
- A competitor does not need to reproduce the exact capsule to compete clinically.
- The commercial market is sensitive to prescription cost and payer coverage.
The practical result is that PYLERA’s remaining value rests more on brand recognition, distribution, and prescribing habits than on a durable exclusionary patent position.
What is the Orange Book status of PYLERA?
PYLERA is associated with FDA NDA 050786. The Orange Book is the authoritative source for current listed patents, pediatric exclusivity, therapeutic-equivalence evaluations, and approved product information.[2]
A market participant should distinguish between three types of competition:
- An authorized or branded generic using the same fixed-dose combination.
- An ANDA product demonstrating pharmaceutical equivalence to PYLERA.
- Separate generic products prescribed as bismuth quadruple therapy.
The third category is already commercially important because physicians can prescribe bismuth, metronidazole, tetracycline, and omeprazole as separate products. That pathway limits PYLERA’s ability to sustain a large premium even without a directly substitutable generic capsule.
Are there Paragraph IV challenges to PYLERA?
Paragraph IV risk is most relevant if a generic sponsor files an ANDA asserting that a listed PYLERA patent is invalid, unenforceable, or not infringed. A successful filing can trigger patent litigation and, in some circumstances, a 30-month stay of FDA approval under the Hatch-Waxman framework.[3]
For a mature fixed-dose combination such as PYLERA, Paragraph IV risk is structurally higher than for a product with a novel active ingredient because:
- The active ingredients have extensive prior art.
- The combination can be assembled from generic materials.
- Formulation claims may face obviousness and written-description challenges.
- The clinical use is well established.
No publicly disclosed Paragraph IV event is necessary for generic erosion to occur. Separate generic prescriptions already create a substitution pathway outside direct Orange Book substitution.
What formulation patents protect the PYLERA capsule?
Formulation protection is the most commercially relevant potential patent category. A fixed-dose capsule must address:
- Compatibility between bismuth salts and antibiotics.
- Stability in storage.
- Uniformity of dose across multiple active ingredients.
- Capsule fill volume and manufacturing controls.
- Patient adherence to a high-frequency regimen.
These issues can raise development and manufacturing costs, but they do not necessarily create a durable market barrier. A generic sponsor may use a different formulation or separate products if it can demonstrate the required pharmaceutical and therapeutic performance.
PYLERA’s four-times-daily schedule also creates a commercial disadvantage. Talicia, for example, uses a different fixed-dose approach and is dosed three times daily with food.[4] Generic bismuth quadruple therapy can be less convenient but is often cheaper.
How does PYLERA compare with Talicia?
Talicia is the closest branded competitive product in U.S. H. pylori therapy. It contains omeprazole, amoxicillin, and rifabutin and was approved by the FDA in 2019.[4]
| Factor |
PYLERA |
Talicia |
| Antibiotic strategy |
Metronidazole plus tetracycline |
Amoxicillin plus rifabutin |
| Bismuth |
Yes |
No |
| Omeprazole included |
No, prescribed separately |
Yes |
| Approval era |
2006 |
2019 |
| Dosing burden |
Three capsules four times daily plus omeprazole |
Four capsules three times daily |
| Main positioning |
Bismuth-based eradication |
Rifabutin-based regimen |
| Generic substitution pressure |
High |
Lower, but increasing over time |
| Resistance rationale |
Useful where clarithromycin resistance is a concern |
Designed for treatment settings involving resistance or prior failure |
| Commercial maturity |
Mature |
Growth-to-maturity transition |
The American College of Gastroenterology recommends optimized bismuth quadruple therapy for many treatment-naive patients and places restrictions on empiric clarithromycin-based therapy where susceptibility is unknown.[5] That recommendation supports PYLERA’s clinical category but does not guarantee use of the branded product. Physicians can select generic components instead.
What is the FDA regulatory status of PYLERA?
PYLERA remains an FDA-approved prescription product for adults with H. pylori infection.[1] Its regulatory status is stable, but the product carries clinically relevant warnings associated with its ingredients.
Key label considerations include:
- Metronidazole-associated neurologic adverse reactions.
- Tetracycline-related photosensitivity and contraindications in pregnancy and young children.
- Bismuth-related stool and tongue discoloration.
- Alcohol avoidance during treatment and for the period specified in labeling because of metronidazole.
- Multiple daily dosing and gastrointestinal tolerability.
Regulatory risk is therefore low in relation to approval maintenance, but labeling, safety monitoring, manufacturing compliance, and supply continuity remain relevant to commercial performance.
How large is the PYLERA market?
AbbVie does not disclose PYLERA revenue as a standalone line item in its annual reports. The product is included within broader pharmaceutical or gastrointestinal portfolio reporting, preventing a reliable public calculation of annual sales, growth rate, gross margin, or geographic contribution.[6]
The addressable market is substantial at the disease level. H. pylori infects a large share of the global population, although prevalence varies by geography, socioeconomic conditions, and diagnostic access.[7] The branded PYLERA market is much narrower because:
- Many infections are untreated or diagnosed outside the prescription channel.
- Generic components are readily available.
- Treatment guidelines permit several regimens.
- Payers may reimburse separate generics more readily than a branded combination.
- Physician choices depend on local resistance patterns and prior treatment history.
Financial trajectory
| Financial driver |
Effect on PYLERA |
| Growing diagnosis and treatment of H. pylori |
Positive volume effect |
| Guideline support for bismuth quadruple therapy |
Positive category effect |
| Separate generic components |
Negative branded-price effect |
| Direct fixed-dose generic entry |
High downside risk |
| Talicia adoption |
Competitive pressure |
| Lack of new chemical entity exclusivity |
Limits pricing power |
| AbbVie portfolio scale |
Supports continued commercialization |
| Product-level revenue disclosure |
Not available publicly |
The likely trajectory is stable-to-declining branded revenue in the absence of a major increase in diagnosis, a new indication, or a material change in treatment guidelines. PYLERA may retain a profitable niche because the product is established and clinically recognized, but it lacks the characteristics of a high-growth specialty medicine.
What generic launch scenarios exist for PYLERA?
Scenario 1: Continued indirect generic erosion
This is the baseline scenario. Physicians continue prescribing separate bismuth, metronidazole, tetracycline, and omeprazole products. PYLERA retains patients who value a packaged regimen, but price-sensitive prescriptions move to individual generics.
Likely effect: gradual volume and price pressure without an abrupt revenue collapse.
Scenario 2: Direct fixed-dose generic approval
A therapeutically equivalent capsule reaches the market. Pharmacy substitution and payer mandates accelerate conversion.
Likely effect: rapid price erosion and material loss of branded prescriptions.
Scenario 3: Branded niche retention
AbbVie maintains distribution, contracting, and physician awareness while direct generic competition remains limited.
Likely effect: stable but mature revenue, supported by convenience and familiarity.
Scenario 4: Clinical displacement
A competing regimen gains preference because of resistance patterns, lower dosing burden, better tolerability, or stronger reimbursement.
Likely effect: declining PYLERA use even without a direct generic launch.
Which companies are challenging PYLERA commercially?
The competitive field includes:
- Generic manufacturers of bismuth, metronidazole, tetracycline, and omeprazole.
- Potential ANDA sponsors seeking a fixed-dose equivalent.
- RedHill Biopharma and commercial partners associated with Talicia.
- Branded and generic suppliers of alternative H. pylori regimens.
- Diagnostic companies that influence treatment volumes through testing adoption.
The main competitive threat does not require a single company to duplicate PYLERA. The regimen itself can be reconstructed through multiple low-cost products.
What licensing and ownership transactions affect PYLERA?
PYLERA originated in the specialty gastrointestinal pharmaceutical market and passed through successive owners before becoming part of AbbVie’s portfolio through the Allergan acquisition. AbbVie completed the Allergan transaction in 2020, adding Allergan’s established products to its pharmaceuticals business.[8]
Public corporate reporting does not provide a separate current PYLERA licensing economics profile, including royalty rates, milestone obligations, or standalone profit-sharing terms. The commercial significance of the product is therefore evaluated within AbbVie’s broader gastrointestinal portfolio rather than through disclosed asset-level transaction metrics.
What patent litigation affects PYLERA?
Patent litigation risk is concentrated in ANDA litigation involving any unexpired Orange Book-listed patent. For a product of PYLERA’s age, the more material risk is often post-exclusivity commercialization rather than a new wave of high-value patent litigation.
Potential disputes can involve:
- Whether a generic capsule uses the claimed ingredient ratios.
- Whether the formulation meets claim limitations.
- Whether method-of-use claims are infringed.
- Whether a listed patent is valid under obviousness standards.
- Whether a generic applicant can carve out a protected indication.
The absence of a currently disclosed major litigation event does not eliminate entry risk. It indicates that the product’s commercial exposure is more likely to arise from ordinary generic competition and treatment substitution.
What geographic markets are important for PYLERA?
The United States is the most important market for evaluating Orange Book, ANDA, and Paragraph IV risk. International exposure depends on country-specific approvals, reimbursement systems, local resistance patterns, and whether the product is sold under the PYLERA name or through equivalent component regimens.
Geographic factors include:
- Higher H. pylori prevalence in parts of Asia, Latin America, Eastern Europe, and the Middle East.
- Greater use of bismuth-based regimens in areas with high clarithromycin resistance.
- Lower branded pricing power in markets with broad generic substitution.
- Different patent terms and regulatory standards outside the United States.
- Variable access to tetracycline and bismuth products.
Global disease prevalence expands the clinical market, but it does not translate directly into branded PYLERA revenue.
What manufacturing and intellectual-property barriers exist?
Manufacturing PYLERA requires reliable sourcing of three active ingredients, consistent blending or filling, capsule stability, and quality control across a high-dose combination. These requirements create operational barriers, but they are manageable for established generic manufacturers.
The strongest practical barrier is execution:
- Securing compliant suppliers.
- Matching capsule performance.
- Demonstrating stability.
- Managing a complex dosing regimen.
- Maintaining reliable supply of tetracycline and metronidazole.
- Meeting FDA current good manufacturing practice requirements.
These barriers may delay competitors, but they are unlikely to preserve premium pricing indefinitely if demand supports a generic entrant.
Key Takeaways
- PYLERA is a mature FDA-approved fixed-dose combination for H. pylori eradication.
- AbbVie owns the product through its Allergan-related portfolio.
- AbbVie does not publicly disclose standalone PYLERA revenue.
- The product’s financial trajectory is likely stable to declining without new commercial support.
- Its strongest market support comes from guideline use of bismuth-based therapy.
- Its primary weakness is that the regimen can be recreated with inexpensive generic components.
- Talicia is the principal branded comparator in the U.S. market.
- Direct ANDA entry would create substantial price and volume risk.
- The product’s patent value is centered on formulation, combination, and method-of-use claims rather than novel-ingredient protection.
- Manufacturing complexity creates a barrier to entry, but not a durable exclusivity moat.
- The U.S. market is most exposed to Orange Book and Paragraph IV risk; international performance depends heavily on local reimbursement and generic policy.
FAQs
Is PYLERA still under patent protection?
PYLERA’s active-ingredient protection has expired, and its commercial position is not based on a novel chemical entity patent. Any remaining listed patent protection should be verified through the current FDA Orange Book and USPTO records.
Is PYLERA available as a generic?
Separate generic components are widely available and can be prescribed as bismuth quadruple therapy. The commercial question is whether an FDA-approved fixed-dose capsule equivalent is available for direct substitution.
Does PYLERA contain omeprazole?
No. PYLERA is prescribed with omeprazole, but omeprazole is not contained in the PYLERA capsule. Talicia includes omeprazole in its fixed-dose product.
Why do physicians still prescribe PYLERA when its ingredients are generic?
The product provides a standardized branded package and reduces the need to assemble several separate prescriptions. Some physicians also value familiarity with its established eradication regimen.
What would most damage PYLERA sales?
A direct fixed-dose generic approval would create the highest immediate risk. Broader use of separate generic bismuth quadruple therapy, stronger Talicia adoption, or a guideline shift away from the regimen would also reduce branded demand.
References
- U.S. Food and Drug Administration. (2023). PYLERA prescribing information.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- U.S. Food and Drug Administration. (2017). Small business assistance: 180-day exclusivity and 30-month stays under Hatch-Waxman.
- U.S. Food and Drug Administration. (2019). Talicia prescribing information.
- American College of Gastroenterology. (2024). ACG clinical guideline: Treatment of Helicobacter pylori infection. The American Journal of Gastroenterology.
- AbbVie Inc. (2024). Annual report for the fiscal year ended December 31, 2023.
- Hooi, J. K. Y., Lai, W. Y., Ng, W. K., Suen, M. M. Y., Underwood, F. E., Tanyingoh, D., et al. (2017). Global prevalence of Helicobacter pylori infection: Systematic review and meta-analysis. Gastroenterology, 153(2), 420-429.
- AbbVie Inc. (2020). AbbVie completes acquisition of Allergan. Press release.
